Lipocine announced that it has completed enrollment in its Phase 2 proof-of-concept study evaluating the therapeutic potential of LPCN 1148 for the management of decompensated cirrhosis of various etiologies. Lipocine intends to explore partnering LPCN 1148. Top-line 24-week results from proof-of-concept study expected mid-2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LPCN:
